Rituximab biosimilar - Biocad

Drug Profile

Rituximab biosimilar - Biocad

Alternative Names: AcellBia; Acellbia; BCD-020

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Biocad
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase III Rheumatoid arthritis

Most Recent Events

  • 11 Nov 2016 Efficacy and adverse events data from a phase III trial in Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
    Session (ACR-ARHP-2016)
  • 29 Jan 2015 Launched for Chronic lymphocytic leukaemia in Russia (IV) after May 2014 - First global launch
  • 29 Jan 2015 Launched for Non-Hodgkin's lymphoma in Russia (IV) after May 2014 - First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top